日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

普拉替尼治疗晚期RET融合阳性非小细胞肺癌患者的I/II期ARROW研究的最终疗效和安全性数据

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-25-01489
Besse, Benjamin; Subbiah, Vivek; Curigliano, Giuseppe; Bowles, Daniel W; Doebele, Robert C; Mansfield, Aaron S; Baik, Christina S; de Lima Lopes, Gilberto; Paz-Ares, Luis; Taylor, Matthew H; Tan, Daniel S W; Alonso, Guzman; Gadgeel, Shirish M; Kalemkerian, Gregory P; Ou, Sai-Hong Ignatius; van der Wekken, Anthonie J; Becerra, Carlos R; Evangelist, Makenzi; Griesinger, Frank; Liu, Stephen V; Lou, Yanyan; Mazières, Julien; Melear, Jason M; Narang, Mohit; Saxena, Ashish; Thomas, Michael; Wang, Sophia; Thomassen, Amber; Lee, Dae Ho; Kim, Dong-Wan; Gainor, Justin F
细胞生物学
肺癌
肿瘤
RET
肿瘤免疫
发表日期：2026
文献求助 收藏

Afatinib in patients with solid tumors with neuregulin 1 (NRG1) fusions: a case series from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

阿法替尼治疗伴有神经调节蛋白1 (NRG1) 融合的实体瘤患者：来自靶向药物和谱系分析应用注册研究 (TAPUR) 的病例系列

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.104545
Rodon, J; Rothe, M; Mangat, P K; Garrett-Mayer, E; Cannon, T L; Hobbs, E; Kalemkerian, G P; Hinshaw, D C; Gregory, A; Grantham, G N; Halabi, S; Schilsky, R L
发表日期：2025
文献求助 收藏

Epidemiology of SCLC in the United States From 2000 to 2019: A Study Utilizing the Surveillance, Epidemiology, and End Results Registry

2000年至2019年美国小细胞肺癌流行病学：一项利用监测、流行病学和最终结果注册库的研究

期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2025.100799
Wells, Leah E; Cohen, Sean; Brennan, Benjamin; Banerjee, Mousumi; Kalemkerian, Gregory P
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

KEYNOTE-604研究中患者报告的健康相关生活质量：帕博利珠单抗或安慰剂联合依托泊苷和铂类药物作为广泛期小细胞肺癌一线治疗方案

期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2023.100572
Kim, Hye Ryun; Awad, Mark M; Navarro, Alejandro; Gottfried, Maya; Peters, Solange; Csőszi, Tibor; Cheema, Parneet K; Rodriguez-Abreu, Delvys; Wollner, Mirjana; Yang, James Chih-Hsin; Mazieres, Julien; Orlandi, Francisco J; Luft, Alexander; Gümüş, Mahmut; Kato, Terufumi; Kalemkerian, Gregory P; Luo, Yiwen; Santorelli, Melissa L; Pietanza, M Catherine; Rudin, Charles M
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM)

尼达尼布治疗复发性恶性胸膜间皮瘤（MPM）II期临床试验简报

期刊:Clinical Lung Cancer
影响因子:3.3
doi:10.1016/j.cllc.2023.04.004
Wozniak, Antoinette J; Schneider, Bryan; Kalemkerian, Gregory P; Daly, Bobby; Chen, Wei; Ventimiglia, Jaclyn; Nagasaka, Misako; Zauderer, Marjorie G
发表日期：2023
文献求助 收藏

Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial

来自 1/2 期 ARROW 试验的普拉替尼治疗 RET 融合阳性实体瘤患者的泛癌疗效

期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-022-01931-y
Subbiah, Vivek; Cassier, Philippe A; Siena, Salvatore; Garralda, Elena; Paz-Ares, Luis; Garrido, Pilar; Nadal, Ernest; Vuky, Jacqueline; Lopes, Gilberto; Kalemkerian, Gregory P; Bowles, Daniel W; Seetharam, Mahesh; Chang, Jianhua; Zhang, Hui; Green, Jennifer; Zalutskaya, Alena; Schuler, Martin; Fan, Yun; Curigliano, Giuseppe
肿瘤
肿瘤免疫
RET
发表日期：2022
文献求助 收藏

Cellular engagement and interaction in the tumor microenvironment predict non-response to PD-1/PD-L1 inhibitors in metastatic non-small cell lung cancer

肿瘤微环境中的细胞参与和相互作用可预测转移性非小细胞肺癌对PD-1/PD-L1抑制剂的无反应性

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-022-13236-8
Qin, Angel; Lima, Fatima; Bell, Samantha; Kalemkerian, Gregory P; Schneider, Bryan J; Ramnath, Nithya; Lew, Madelyn; Krishnan, Santhoshi; Mohammed, Shariq; Rao, Arvind; Frankel, Timothy L
肺癌
肿瘤
肿瘤免疫
PD-L1
细胞生物学
肿瘤微环境
PD-1
发表日期：2022
文献求助 收藏

Characterization of pneumonia and other factors leading to poorer survival across all age groups in patients with non-small cell lung cancer (NSCLC)

非小细胞肺癌（NSCLC）患者各年龄段肺炎及其他导致生存率降低的因素的特征分析

期刊:Journal of Thoracic Disease
影响因子:1.9
doi:10.21037/jtd-20-2891
Weinberg, Frank D; Zhao, Lili; Chellappa, Niranjana; Kalemkerian, Gregory P; Ramnath, Nithya
肺炎
肺癌
肿瘤
肿瘤免疫
CLC
细胞生物学
发表日期：2021
文献求助 收藏

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

帕博利珠单抗或安慰剂联合依托泊苷和铂类药物作为广泛期小细胞肺癌一线治疗：一项随机、双盲、III期KEYNOTE-604研究

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.20.00793
Rudin, Charles M; Awad, Mark M; Navarro, Alejandro; Gottfried, Maya; Peters, Solange; Csőszi, Tibor; Cheema, Parneet K; Rodriguez-Abreu, Delvys; Wollner, Mirjana; Yang, James Chih-Hsin; Mazieres, Julien; Orlandi, Francisco J; Luft, Alexander; Gümüş, Mahmut; Kato, Terufumi; Kalemkerian, Gregory P; Luo, Yiwen; Ebiana, Victoria; Pietanza, M Catherine; Kim, Hye Ryun
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2020
文献求助 收藏

High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients

从非小细胞肺癌患者中高通量无标记分离异质性循环肿瘤细胞和 CTC 簇

期刊:Cancers
影响因子:
doi:10.3390/cancers12010127
Mina Zeinali, Maggie Lee, Arthi Nadhan, Anvya Mathur, Casey Hedman, Eric Lin, Ramdane Harouaka, Max S Wicha, Lili Zhao, Nallasivam Palanisamy, Mathias Hafner, Rishindra Reddy, Gregory P Kalemkerian, Bryan J Schneider, Khaled A Hassan, Nithya Ramnath, Sunitha Nagrath
肿瘤
肺癌
肿瘤细胞
发表日期：2020
文献求助 收藏